Biological Age Clocks: The Regulatory Reckoning Is Coming
With $3.74 billion flowing into longevity biotech in Q1 2026 alone, investors are backing biological age diagnostics that regulators cannot yet validate. The collision between capital and clinical evidence is building.
GDF-15 and P-tau217: The Biomarkers That Signal Breakdown Before You Feel It
Two biomarkers — GDF-15 for cellular stress and P-tau217 for Alzheimer's risk — can flag physiological strain years before symptoms appear. Here's what they measure, what trends reveal, and why a single reading misses the point.
Peter Attia Episode 404: Why the Neurotransmitter Model of Mental Health Is Incomplete
Dr. Linus Abrams argues that psychiatry's focus on symptom reduction through medication overlooks the hormonal, metabolic, and inflammatory drivers of mental health. The implications for how practitioners and patients think about mental wellbeing are significant.
The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
AgelessRx has been selected as one of 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition, earning $1M to advance a one-year randomized trial testing a six-component antiaging protocol including low-dose rapamycin, NAD+, and metformin.
Menopause Is a Muscle-Health Inflection Point — and Most Programs Miss It
Estrogen decline during menopause narrows the window for muscle protein synthesis and changes how training responds. The intervention stack is specific: protein distribution, progressive resistance, and individualized HRT consideration — not just more of each.
5 Perimenopause Supplements That Actually Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are under-dosed marketing. This evidence-graded breakdown identifies five options that hold up on clinical data, labeled doses, and standardized extracts.
5 Perimenopause Supplements That Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are underdosed and opaque. This evidence-graded breakdown applies clinical trial dosing standards to the current field — here are the five that survive scrutiny.
Blood Filtering Is the New Wellness Flex — And Viome Just Bought the Infrastructure
Viome's acquisition of Circulate Health pairs multi-omics biomarker testing with therapeutic plasma exchange. What this convergence means for longevity-focused consumers navigating an increasingly clinical wellness stack.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.
Healthy Aging: Why Exercise Is Non-Negotiable and Protein Is Supporting Cast
New research reframes the protein-first aging model. Exercise is the irreducible core of healthy aging — protein helps, but it doesn't replace what movement does at the cellular level.
Protein Restriction for Kidney Disease: What the Evidence Actually Shows
Peter Attia reviews the MDRD trial and Cochrane data: the default CKD advice to restrict protein lacks the evidence base it's been given — and the biggest trial showed higher long-term mortality in the restriction group.
Aging Research Has Been Studying the Wrong Sex
The Reproductive Resilience Hypothesis, published in Cell, argues female biology holds the key to understanding longevity — but most aging research has treated it as experimental noise.
One Shot, Five Organs: FGF21 Gene Therapy Extends Mouse Healthspan by 20%
A single AAV injection of FGF21 extended median lifespan by over 20% in aged mice, protecting liver, kidneys, heart, muscle, and brain — and it worked after age-related decline had already begun.
Human Longevity's $599 Genomics for All: What Clinical-Grade DNA Sequencing Gets You Now
Human Longevity sequences all 6.4 billion base pairs at $599 — and an AI layer re-alerts you as science evolves. What it covers, who it's actually for, and why the re-analysis matters more than the price.
The Bathroom as a Longevity Clinic: What Vivoo's Passive Monitoring Stack Changes
Vivoo's urinalysis platform and toilet-integrated hydration monitor embed daily biomarker collection into existing routines. What it covers, why passive beats active testing, and where this sits in a complete longevity stack.
NMR Blood Testing: One Blood Sample, Four Different Risk Scores
A single NMR blood scan reveals heart disease, insulin resistance, inflammation, and mortality risk — the inventor explains why one draw beats a standard panel.
Metabolic Health: Why GLP-1s Were Never the Whole Answer
GLP-1 drugs sparked the metabolic health boom, but the platforms building around it are betting the real product is what happens after the prescription.
Niagen's NR Study: A 2.5-Year Drop in Muscle Epigenetic Age
A new peer-reviewed analysis links NR supplementation to a 2.5-year reduction in muscle epigenetic age — though the funding company calls the data preliminary.
Living Near a Data Center Without Wrecking Your Sleep
Data centers bring measurable noise, EMF, heat, and air exposure to nearby homes. A practical framework for measuring and mitigating each risk.
Timeline Wins $5.3M Judgment Against Fake Urolithin A Sellers
A federal court awarded Timeline $5.3M and permanent injunctions against 19 counterfeit urolithin A sellers — a case that signals the longevity supplement market is finally getting real enforcement.
Ultrahuman's Emerald Update Answers a Question Wearables Kept Ignoring
Ultrahuman's Emerald overhaul replaces spreadsheet-style metrics with a decision engine that tells you what to actually do next — plus a VO2 max algorithm validated to lab-grade accuracy.
Peter Attia's Framework for Environmental Threats to Longevity: Air, Noise, and Light
AMA #87 applies Attia's 80/20 principle to chronic environmental exposures — PM2.5, noise, and artificial light — and which interventions actually move the longevity needle.
Heat Training Boosts Hemoglobin — But Can It Make You Faster?
Heat training reliably raises hemoglobin mass by 2–5%. But 5 of 6 trials find no clear performance payoff in VO₂max or sport results. Here's what the evidence actually shows.
Dumbo Health Is Turning Sleep Into a Clinical Longevity Metric — Here's What That Means
Miami-based Dumbo Health launched Sleep Longevity: 51 blood biomarkers, wearable data, and physician care in one membership. The 90% of women with undiagnosed sleep apnea are the real target.